Literature DB >> 2884810

Schneiderian first rank symptoms: reconfirmation of high specificity for schizophrenia.

R Tandon, J F Greden.   

Abstract

The prevalence of Schneiderian first-rank symptoms (FRS) in 294 consecutive admissions to a research unit was evaluated with reference to their diagnostic distribution (SADS/RDC). Thirty-five of 58 patients with schizophrenia had FRS, as compared to nine of 190 patients with major depressive disorder. All patients with two or more FRS received a diagnosis of schizophrenia. In the absence of organic or toxic etiology, the specificity of FRS for schizophrenia was 95% and their predictive value was 90%. These findings indicate that FRS should be regarded as strongly suggestive of schizophrenia in the absence of an organic syndrome.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2884810     DOI: 10.1111/j.1600-0447.1987.tb02807.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  5 in total

Review 1.  First rank symptoms for schizophrenia.

Authors:  Karla Soares-Weiser; Nicola Maayan; Hanna Bergman; Clare Davenport; Amanda J Kirkham; Sarah Grabowski; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2015-01-25

2.  The concept of psychosis: historical and phenomenological aspects.

Authors:  Martin Bürgy
Journal:  Schizophr Bull       Date:  2008-01-03       Impact factor: 9.306

3.  [The history and phenomenology of the concept of psychosis. A perspective of the Heidelberg school (1913-2008)].

Authors:  M Bürgy
Journal:  Nervenarzt       Date:  2009-05       Impact factor: 1.214

Review 4.  Competing definitions of schizophrenia: what can be learned from polydiagnostic studies?

Authors:  Lennart B Jansson; Josef Parnas
Journal:  Schizophr Bull       Date:  2006-12-08       Impact factor: 9.306

Review 5.  The diagnostic status of first-rank symptoms.

Authors:  Julie Nordgaard; Sidse M Arnfred; Peter Handest; Josef Parnas
Journal:  Schizophr Bull       Date:  2007-06-11       Impact factor: 9.306

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.